

References

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer's disease. *Annu Rev Public Health*. 1992;13:431-449.
3. Breteler MM, Claus JJ, van Duijn CM, Launer LJ, Hofman A. Epidemiology of Alzheimer's disease. *Epidemiol Rev*. 1992;14:59-82.
4. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. *Am J Psychiatry*. 2000;157:1686-1689.
5. O'Connor D, Pollitt P, Hyde J, Brook C, Reiss B, Roth M. Do general practitioners miss dementia in elderly patients? *Br Med J*. 1988;297:1107-1110.
6. Cooper B, Bickel H, Schaafle M. Early development and progression of dementing illness in the elderly: a general-practice based study. *Psycholog Med*. 1996;26:411-419.
7. Lagaay A, van der Meij J, Hijmans W. Validation of medical history taking as part of a population based survey in subjects aged 85 and over. *Br Med J*. 1992;304:1091-1092.
8. Iliffe S, Mitchley S, Gould M, Haines A. Evaluation of the use of brief screening instruments for dementia, depression and problem drinking among elderly people in general practice. *Brit J Gen Pract*. 1994;44:503-507.
9. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. *Am J Public Health*. 1994;84:1261-1264.
10. Evans D. Estimated prevalence of Alzheimer's disease in the United States. *Milbank Q*. 1990;68:267-289.
11. van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. *Int J Epidemiol*. 1991;20 Suppl 2:S13-S20.
12. Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. *Dement Geriatr Cogn Disord*. 2000;11:223-229.
13. Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. *J Am Geriatr Soc*. 2000;48:1430-1434.
14. Valcour V, Masaki K, Curb J, Blanchette P. The detection of dementia in the primary care setting. *Arch Intern Med*. 2000;160:2964-2968.
15. US Preventive Services Task Force. Screening for Dementia. *Guide to Clinical Preventive Services*. 2nd Ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996.
16. Patterson CJ, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. *Can Med Assoc J*. 1999;160:S1-S15.
17. Canadian study of health and aging: study methods and prevalence of dementia. *Can Med Assoc J*. 1994;150:899-913.
18. Evans D, Funkenstein H, Albert M, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. *JAMA*. 1989;262:2551-2556.
19. Office of Technology Assessment. *Losing a Million Minds: Confronting the Tragedy of AD and Other Dementias*. Washington, DC: US Government Printing Office; 1987.
20. General Accounting Office. Estimates of prevalence in the United States. Washington DC: US General Accounting Office; 1998;Publication HEHS98-16.
21. Evans D, Smith L, Scherr P, Albert M,

- Funkenstein H, Hebert L. Risk of death from Alzheimer's disease in a community population of older persons. *Am J Epidemiol.* 1991;134:403-412.
22. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *Am J Public Health.* 1998;88:1337-1342.
23. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. *Natl Vital Stat Rep.* 1999;47:1-104.
24. Wolfson C, Wolfson D, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. *N Engl J Med.* 2001;344:1111-1116.
25. Ganguli M. The use of screening instruments for the detection of dementia. *Neuroepidemiology.* 1997;16:271-280.
26. Brodaty H, Clarke J, Ganguli M, et al. Screening for cognitive impairment in general practice: toward a consensus. *Alzheimer Dis Assoc Disord.* 1998;12:1-13.
27. Dunkin J, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. *Neurology.* 1998;51:S53-S60; discussion S65-S67.
28. Schulz R, O'Brien A, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. *Gerontologist.* 1995;35:771-791.
29. Bedard M, Pedlar D, Martin N, Malott O, Stones M. Burden in caregivers of cognitively impaired older adults living in the community: methodological issues and determinants. *Int Psychogeriatr.* 2000;12:307-332.
30. Grafstrom M, Fratiglioni L, Sandman P, Winblad B. Health and social consequences for relatives of demented and non-demented elderly. A population-based study. *J Clin Epidemiol.* 1992;45:861-870.
31. Molloy D, Lever J, Bedard M, Guyatt G, Butt G. Burden and caregivers of older adults with impaired cognition: relationship with dysfunctional behavior. Daily living and mood. *Ann R Coll Physicians Surg Can.* 1996;29:151-154.
32. Newens A, Forster D, Kay D. Dependency and community care in presenile Alzheimer's disease. *Br J Psychiatry.* 1995;166:777-782.
33. Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL. Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity. *J Am Geriatr Soc.* 1988;36:784-790.
34. Rabins P, Mace N, Lucas M. The impact of dementia on the family. *JAMA.* 1982;248:333-335.
35. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. *Gerontologist.* 1993;33:714-720.
36. Gold DP, Reis MF, Markiewicz D, Andres D. When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia. *J Am Geriatr Soc.* 1995;43:10-16.
37. McFall S, Miller BH. Caregiver burden and nursing home admission of frail elderly persons. *J Gerontol.* 1992;47:S73-S79.
38. Tsuji I, Whalen S, Finucane TE. Predictors of nursing home placement in community-based long-term care. *J Am Geriatr Soc.* 1995;43:761-766.
39. Brandt J. Mild cognitive impairment in the elderly. *Am Fam Physician.* 2001;63:620, 622, 625-626.
40. Hanninen T, Hallikainen M, Koivisto K, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. *J Am Geriatr Soc.* 1995;43:1007-1015.
41. Morris J, Storandt M, Miller J, et al. Mild cognitive impairment represents early-stage Alzheimer disease. *Arch Neurol.* 2001;58:397-405.
42. Jorm A, Jolley D. The incidence of dementia: a meta-analysis. *Neurology.* 1998;51:728-733.
43. Lautenschlager N, Cupples L, Rao V, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? *Neurology.*

- 1996;46:641-650.
44. Blacker D, Tanzi R. The genetics of Alzheimer disease: current status and future prospects. *Arch Neurol*. 1998;55:294-296.
45. Lai F, Williams R. A prospective study of Alzheimer disease in Down syndrome. *Arch Neurol*. 1989;46:849-853.
46. Longstreth W Jr, Bernick C, Manolio T, Bryan N, Jungreis C, Price T. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. *Arch Neurol*. 1998;55:1217-1225.
47. Hofman A, Ott A, Breteler M, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. *Lancet*. 1997;349:151-154.
48. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. *N Engl J Med*. 1993;328:153-158.
49. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189-198.
50. Schulman K. Clock-drawing: is it the ideal cognitive screening test? *Int J Geriatr Psychiat*. 2000;15:548-561.
51. Pfeffer R, Kurosaki T, Harrah CJ, Chance J, Filos S. Measurement of functional activities in older adults in the community. *J Gerontol*. 1982;37:323-329.
52. Fuh JL, Teng EL, Lin KN, et al. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening tool for dementia for a predominantly illiterate Chinese population. *Neurology*. 1995;45:92-96.
53. Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. *J Am Geriatr Soc*. 1992;40:1129-1134.
54. Jorm A. Assessment of cognitive impairment and dementia using informant reports. *Clin Psychol Rev*. 1996;16:51-73.
55. Lovestone S. Early diagnosis and the clinical genetics of Alzheimer's disease. *J Neurology*. 1999;246:69-72.
56. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34:939-944.
57. Cunha UG. An investigation of dementia among elderly outpatients. *Acta Psychiatr Scand*. 1990;82:261-263.
58. Ames D, Flicker L, Helme RD. A memory clinic at a geriatric hospital: rationale, routine and results from the first 100 patients. *Med J Aust*. 1992;156:618-622.
59. Massoud F, Devi G, Moroney JT, et al. The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study. *J Am Geriatr Soc*. 2000;48:1204-1210.
60. Walstra GJ, Teunisse S, van Gool WA, van Crevel H. Reversible dementia in elderly patients referred to a memory clinic. *J Neurol*. 1997;244:17-22.
61. Freter S, Bergman H, Gold S, Chertkow H, Clarfield AM. Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. *Can Med Assoc J*. 1998;159:657-662.
62. Clarfield A. The reversible dementias: do they reverse? *Ann Intern Med*. 1988;109:476-486.
63. Conwell Y, Caine E. Rational suicide and the right to die. Reality and myth. *N Engl J Med*. 1991;325:1100-1103.
64. Rohde K, Peskind E, Raskind M. Suicide in two patients with Alzheimer's disease. *J Am Geriatr Soc*. 1995;43:187-189.
65. Harris R, Helfand M, Woolf S, et al. Current methods of the US Preventive Services Task Force: A review of the process. *Am J Prev Med*. 2001;2 (3S):21-35.
66. Eefsting J, Boersma F, Van den Brink W, Van Tilburg W. Differences in prevalence of dementia based on community survey and

- general practitioner recognition. *Psycholog Med.* 1996;26:1223-1230.
67. Hendrie H, Osuntokun B, Hall K, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. *Am J Psychiatry.* 1995;152:1485-1492.
68. White L, Petrovitch H, Ross G, et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. *JAMA.* 1996;276:955-960.
69. Graves A, Larson E, Edland S, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project. *Am J Epidemiol.* 1996;144:760-771.
70. Corrada M, Brookmeyer R, Kawas C. Sources of variability in prevalence rates of Alzheimer's disease. *Int J Epidemiol.* 1995;24:1000-1005.
71. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. *N Engl J Med.* 1997;337:1667-1674.
72. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. *Neurology.* 1999;53:321-331.
73. Gurland B, Wilder D, Lantigua R, et al. Rates of dementia in three ethnoracial groups. *Int J Geriatr Psychiatry.* 1999;14:481-493.
74. Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. *J Gerontol.* 1985;40:536-543.
75. Costa PT Jr, Williams T, Somerfield M, et al. Early identification of Alzheimer's disease and related dementias. *Clinical Practice Guideline, Quick Reference Guide for Clinicians, No. 19.* Rockville, MD: AHCPR Publication No. 97-0703; 1996: 19:1-28.
76. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol.* 1997;50:377-383.
77. Lindeboom J, Launer LJ, Schmand BA, Hooyer C, Jonker C. Effects of adjustment on the case-finding potential of cognitive tests. *J Clin Epidemiol.* 1996;49:691-695.
78. Jitapunkul S, Lailert C, Worakul P, Srikiatkachorn A, et al. Chula Mental Test: A screening test for elderly people in less developed countries. *Int J Geriatr Psychiatry.* 1996;11:714-720.
79. Braekhus A, Laake K, Engedal K. A low, 'normal' score on the Mini-Mental State Examination predicts development of dementia after three years. *J Am Geriatr Soc.* 1995;43:656-661.
80. Wilder D, Cross P, Chen J, et al. Operating characteristics of brief screens for dementia in a multicultural population. *Am J Geriatric Psychiatry.* 1995;3:96-107.
81. Heun R, Papassotiropoulos A, Jenissen F. The validity of psychometric instruments for detection of dementia in the elderly general population. *Int J Geriatr Psychiatry.* 1998;13:368-380.
82. Solomon PR, Brush M, Calvo V, et al. Identifying dementia in the primary care practice. *Int Psychogeriatr.* 2000;12:483-493.
83. Barberger-Gateau P, Fabrigoule C, Helmer C, Rouch I, Dartigues J. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? *J Am Geriatr Soc.* 1999;47:456-462.
84. Law S, Wolfson C. Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer's disease. *Br J Psychiatry.* 1995;167:541-544.
85. Hasselblad V, Hedges L. Meta-analysis of screening and diagnostic tests. *Psychol Bull.* 1995;117:167-178.
86. Jorm AF. Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test. *Alzheimer Dis Assoc Disord.* 1997;11:158-162.
87. Barberger-Gateau P, Dartigues JF, Letenneur L. Four Instrumental Activities of Daily Living Score as a predictor of one-year incident dementia. *Age Ageing.* 1993;22:457-463.

88. Stern R, Mohs R, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. *Am J Psychiatry*. 1994;151:390-396.
89. Weytingh M, Bossuyt P, van Crevel H. Reversible dementia: more than 10% or less than 1%? A quantitative review. *J Neurol*. 1995;242:466-471.
90. Cunha UG, Rocha FL, Peixoto JM, Motta MF, Barbosa MT. Vitamin B12 deficiency and dementia. *Int Psychogeriatr*. 1995;7:85-88.
91. Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. *Int J Geriatr Psychiatry*. 2000;15:226-233.
92. Larson EB, Reifler BV, Featherstone HJ, English DR. Dementia in elderly outpatients: a prospective study. *Ann Intern Med*. 1984;100:417-423.
93. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology*. 2001;57:489-495.
94. Devanand D, Marder K, Michaels K, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. *Am J Psychiatry*. 1998;155:1512-1520.
95. Mohs R, Doody R, Morris J, Rogers S, Pratt R. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year prospective placebo-controlled functional survival study. *Neurology*. 2001.
96. Wilcock G, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. *Br Med J*. 2000;321:1445-1449.
97. Raskind M, Peskind E, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. *Neurology*. 2000;54:2261-2268.
98. Tariot P, Solomon P, Morris J, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. *Neurology*. 2000;54:2269-2276.
99. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. *Dement Geriatr Cogn Disord*. 1999;10:237-244.
100. Greenberg S, Tennis M, Brown L, et al. Donepezil therapy in clinical practice: a randomized crossover study. *Arch Neurol*. 2000;57:94-99.
101. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *Br Med J*. 1999;318:633-638.
102. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet*. 2000;356:2031-2036.
103. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med*. 1997;336:1216-1222.
104. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. *J Neurol Sci*. 2000;175:124-134.
105. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. *JAMA*. 2000;283:1007-1015.
106. Le Bars P, Katz M, Berman N, Itil T, Freedman A, Schatzberg A. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. *JAMA*. 1997;278:1327-1332.
107. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. *J Psychiatr Res*. 1997;31:645-655.
108. Aisen P, Davis K, Berg J, et al. A randomized

- controlled trial of prednisone in Alzheimer's disease. *Alzheimer's Disease Cooperative Study. Neurology.* 2000;54:588-593.
109. Scharf S, Mander A, Ugoni A, Vajda F, Christopidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. *Neurology.* 1999;53:197-201.
110. Auchus A, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci.* 1997;9:591-593.
111. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein S. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. *J Neuropsychiatry Clin Neurosci.* 1996;8:270-275.
112. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. *Int J Geriatr Psychiatry.* 2001;16:852-857.
113. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. *Neurology.* 2000;55:1271-1278.
114. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. *Neurology.* 2001;57:605-612.
115. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD001191.
116. Birks J, Flicker L. Selegiline for Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD000442.
117. Williams P, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. *Cochrane Database Syst Rev.* 2000;CD001296.
118. Oken B, Storzbach D, Kaye J. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. *Arch Neurol.* 1998;55:1409-1415.
119. Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD001190.
120. Qizilbash N, Birks J, Lopez A, Lewington S, Szeto S. Tacrine for Alzheimer's disease. [update of: 20257597] (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD000202.
121. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. *Dementia Trialists' Collaboration. JAMA.* 1998;280:1777-1782.
122. Lanctot K, Best T, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. *J Clin Psychiatry.* 1998;59:550-561; quiz 562-563.
123. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. *Br J Psychiatry.* 1990;157:72-76, 92-94.
124. Davidson M, Weiser M, Soares K. Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials. *Int Psychogeriatr.* 2000;12:271-277.
125. Kirchner V, Kelly C, Harvey R. Thioridazine for dementia (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD000464.
126. Demers L, Oremus M, Perrault A, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: introduction. *J Geriatr Psychiatry Neurol.* 2000;13:161-169.
127. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. *Am J Psychiatry.* 1984;141:1356-1364.
128. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. *The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord.* 1997;11 Suppl 2:S13-S21.
129. McDowell I, Newell C; *Measuring Health. A Guide to Rating Scales and Questionnaires.* Second ed. Oxford: Oxford University Press; 1996.
130. Solomon P, Adams F, Groccia M, DeVeaux R, Growdon J, Pendlebury W. Correlational analysis of five commonly used measures of mental status/functional abilities in patients with

- Alzheimer disease. *Alzheimer Dis Assoc Disord.* 1999;13:147-150.
131. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. *Neurology.* 1997;48:1511-1517.
132. Vitaliano PP, Breen AR, Albert MS, Russo J, Prinz PN. Memory, attention, and functional status in community-residing Alzheimer type dementia patients and optimally healthy aged individuals. *J Gerontol.* 1984;39:58-64.
133. Perry RJ, Hodges JR. Relationship between functional and neuropsychological performance in early Alzheimer disease. *Alzheimer Dis Assoc Disord.* 2000;14:1-10.
134. McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer's disease trials: the donepezil experience. *J Geriatr Psychiatry Neurol.* 1999;12:39-48.
135. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord.* 1997;11 Suppl 3:8-18.
136. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. *Gerontologist.* 1970;10:20-30.
137. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist.* 1969;9:179-186.
138. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. *J Am Geriatr Soc.* 1986;34:722-727.
139. Nasr S, Osterweil D. The nonpharmacologic management of agitation in the nursing home: a consensus approach. *Annals of Long-Term Care.* 1999;7:171-180.
140. Perrault A, Oremus M, Demers L, Vida S, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of behavior and mood scales. *J Geriatr Psychiatry Neurol.*
- 2000;13:181-196.
141. Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. *Dement Geriatr Cogn Disord.* 2000;11:147-152.
142. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. *J Am Geriatr Soc.* 1997;45:321-328.
143. Lyketsos C, Steinberg M, Tschanz J, Norton M, Steffens D, Breitner J. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. *Am J Psychiatry.* 2000;157:708-714.
144. Lyketsos C. *Clinical Aspects of Aging*, 5th Ed. Oxford : Oxford University Press; 1999.
145. Hamel M, Gold D, Andres D, et al. Predictors and consequences of aggressive behavior by community-based dementia patients. *Gerontologist.* 1990;30:206-211.
146. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. *Psychopharmacol Bull.* 1988;24:458-462.
147. Brooks JO 3rd, Yesavage JA, Taylor J, et al. Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. *Int Psychogeriatr.* 1993;5:135-146.
148. Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. *Neurology.* 1990;40:1225-1230.
149. Food and Drug Administration; Peripheral and central nervous system drugs advisory committee meeting. Rockville, MD: Dept. of Health and Human Services, Public Health Service; 1989;227.
150. Mastey V, Wimo A, Winblad B, et al. *An economic evaluation of donepezil in mild to moderate Alzheimer's disease; results of a one-year, double-blind, randomized trial.* Chicago: American Geriatric Society meeting ; 2001.
151. Forbes D. Strategies for managing behavioural

- symptomatology associated with dementia of the Alzheimer type: a systematic overview. *Can J Nurs Res.* 1998;30:67-86.
152. Friedman R, Tappen RM. The effect of planned walking on communication in Alzheimer's disease. *J Am Geriatr Soc.* 1991;39:650-654.
153. Rosswurm M. Attention-focusing program for persons with dementia. *Clin Gerontologist.* 1991;10(2):3-16.
154. Tappen RM. The effect of skill training on functional abilities of nursing home residents with dementia. *Res Nurs Health.* 1994;17:159-165.
155. Opie J, Rosewarne R, O'Connor D. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. *Aust N Z J Psychiatry.* 1999;33:789-799.
156. Rovner BW, Steele CD, Shmuely Y, Folstein MF. A randomized trial of dementia care in nursing homes. *J Am Geriatr Soc.* 1996;44:7-13.
157. Hinchliffe A, Hyman I, Blizzard B, Livingston G. Behavioural complications of dementia - can they be treated? *Int J Geriatr Psychiatry.* 1995;10:839-847.
158. Burgener SC, Bakas T, Murray C, Dunahue J, Tossey S. Effective caregiving approaches for patients with Alzheimer's disease. *Geriatr Nurs.* 1998;19:121-126.
159. Robichaud L, Hebert R, Desrosiers J. Efficacy of a sensory integration program on behaviors of inpatients with dementia. *Am J Occup Ther.* 1994;48:355-60.
160. Koger S, Brotons M. Music therapy for dementia symptoms (Cochrane Review). *Cochrane Database Syst Rev.* 2000;CD001121.
161. Neal M, Briggs M. Validation therapy for dementia (Cochrane Review). *Cochrane Database Syst Rev.* 2000;2.
162. Spector A, Orrell M, Mavies S, Woods R. Reminiscence therapy for dementia. *Cochrane Database Syst Rev.* 2000;4.
163. Spector A, Orrell M, Davies S, Woods B. Reality orientation for dementia. *Cochrane Database Syst Rev.* 2000;CD001119.
164. Bedard M, Molloy D, Pedlar D, Lever J, Stones M. 1997 IPA/Bayer Research Awards in Psychogeriatrics. Associations between dysfunctional behaviors, gender, and burden in spousal caregivers of cognitively impaired older adults. *Int Psychogeriatr.* 1997;9:277-290.
165. George L, Gwyther L. Caregiver well-being: a multidimensional examination of family caregivers of demented adults. *Gerontologist.* 1986;26:253-259.
166. Kiecolt-Glaser J, Dura J, Speicher C, Trask O, Glaser R. Spousal caregivers of dementia victims: longitudinal changes in immunity and health. *Psychosom Med.* 1991;53:345-362.
167. Gallagher D, Rose J, Rivera P, Lovett S, Thompson LW. Prevalence of depression in family caregivers. *Gerontologist.* 1989;29:449-456.
168. Deimling G, Bass D. Symptoms of mental impairment among elderly adults and their effects on family caregivers. *J Gerontol.* 1986;41:778-784.
169. Pruchno R, Resch N. Aberrant behaviors and Alzheimer's disease: mental health effects on spouse caregivers. *J Gerontol.* 1989;44:S177-S182.
170. Cohen-Mansfield J, Werner P. Typology of disruptive vocalizations in older persons suffering from dementia. *Int J Geriatr Psychiatry.* 1997;12:1079-1091.
171. Mangone C, Sanguinetti R, Baumann P, et al. Influence of feelings of burden on the caregiver's perception of the patient's functional status. *Dementia.* 1993;4:287-293.
172. Thompson C, Briggs M. Support for carers of people with Alzheimer's type dementia (Cochrane Review). *Cochrane Database of Sys Rev.* 2000.
173. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. *JAMA.* 1996;276:1725-1731.
174. Marriott A, Donaldson C, Tarrier N, Burns A. Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. *Br J*

- Psychiatry.* 2000;176:557-562.
175. McCurry SM, Logsdon RG, Vitiello MV, Teri L. Successful behavioral treatment for reported sleep problems in elderly caregivers of dementia patients: a controlled study. *J Gerontol B Psychol Sci Soc Sci.* 1998;53:122-P1299.
176. Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital dementia caregivers' training programme. *Int J Geriatr Psychiatry.* 1997;12:183-192.
177. Hebert R, Leclerc G, Bravo G, Girouard D, Lefrancois R. Efficacy of a support group programme for caregivers of demented patients in the community: a randomized controlled trial. *Arch Gerontol Geriatr.* 1994;18:1-14.
178. Hebert R, Girouard D, Leclerc G, Bravo G, Lefrancois R. The impact of a support group programme for care-givers on the institutionalization of demented patients. *Arch Gerontol Geriatr.* 1995;20:129-134.
179. Jorm A, Henderson A, Scott R, Mackinnon A, Korten A, Christensen H. Do mental health surveys disturb? Further evidence. *Psychol Med.* 1994;24:233-237.
180. Petersen R, Stevens J, Ganguli M, Tangalos E, Cummings J, DeKosky S. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2001;56:1133-1142.
181. Patterson CJ, Gass DA. Screening for cognitive impairment and dementia in the elderly. *Can J Neurol Sci.* 2001;28 Suppl 1:S42-S51.
182. Drickamer MA, Lachs MS. Should patients with Alzheimer's disease be told their diagnosis? *N Engl J Med.* 1992;326:947-951.
183. Jha A, Tabet N, Orrell M. To tell or not to tell—comparison of older patients' reaction to their diagnosis of dementia and depression. *Int J Geriatr Psychiatry.* 2000;176:557-562.
- Geriatr Psychiatry.* 2001;16:879-885.
184. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet.* 1998;352:1347-1351.
185. Applegate WB, Pressel S, Witten J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. *Arch Intern Med.* 1994;154:2154-2160.
186. Prince MJ, Bird AS, Blizzard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. *Br Med J.* 1996;312:801-805.
187. Dartigues JF, Commenges D, Letenneur D, et al. Cognitive predictors of dementia in elderly community residents. *Neuroepidemiology.* 1997;16:29-39.
188. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. *Br J Psychiatry.* 1982;140:566-572.
189. Gottfries CG, Brane G, Gullberg B, Steen G. A new rating scale for dementia syndromes. *Arch Gerontol Geriatr.* 1982;1:311-30.
190. Brane G, Gottfries CG, Winblad B. The Gottfries-Brane-Steen scale: validity, reliability and application in anti-dementia drug trials. *Dement Geriatr Cogn Disord.* 2001;12:1-14.
191. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gormbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology.* 1994;44:2308-2314.
192. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. *Clin Ther.* 1989;11:545-54.